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Figure 4. Effects of VK4-40 pretreatment on total ambulations over 120 min following
saline i.p. (n=16). **p=0.001, VK4-40 compared to vehicle. Each data point represents
Proestrus=
mean ±SEM total ambulations.
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VK4-40 attenuates locomotion only at the highest dose
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Figure 1. Dose-response showing effects of VK4-40 pretreatment on total ambulations (A) 60 minutes following cocaine injections
(n=16) and (B) 120 minutes following morphine injections (n=16). ***p<0.001, VK4-40 compared to vehicle at 5.6 mg/kg morphine.
****p<0.0001, VK4-40 compared to vehicle at 18 mg/kg morphine. Each data point represents mean ±SEM total ambulations.
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Figure 5. Time course effects of locomotion following pretreatment with VK4-40. Vehicle,
3, 10, or 20 mg/kg of VK4-40 was administered 30 min before saline. Each data point
represents mean ±SEM total ambulations recorded in 5-min bins.
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• 4-hour locomotor activity sessions

Time course: VK4-40 + Morphine
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VK4-40 attenuates morphine-induced hyperactivity
at doses that do not affect basal locomotion

•

Highly selective dopamine D3 receptor antagonists
have potential in treating opioid use disorder
without enhancing effects of cocaine
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Figure 3. Time course effects of cocaine-induced locomotion following pretreatment with VK4-40. Vehicle, 3, 10, or 20 mg/kg of
VK4-40 was administered 30 min prior to (A) 3 mg/kg cocaine, or (B) 10 mg/kg cocaine. Each data point represents mean ±SEM total
ambulations recorded in 5-min bins.

Group 1: VK4-40 (veh, 3, 10, 20 mg/kg) and cocaine (3, 10 mg/kg)
Group 2: VK4-40 (veh, 3, 10, 20 mg/kg) and morphine (0, 5.6, 18 mg/kg)

240 min
90 min 120 min
Ambulations were recorded for 4 h. Cocaine data were analyzed 60 min postcocaine injection, whereas morphine was analyzed 120 min post-injection.
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Methods

1st

VK4-40 dose-response (prior to saline)

B

The purpose of this study was to examine the impact of pretreatment with the
novel and highly selective D3R antagonist VK4-40 (250-fold selectivity for D3R
vs. D2R) on cocaine- and morphine-induced hyperlocomotion in mice.

16 locomotor activity chambers (above; left. San Diego Instruments; San Diego,
California) were used to measure horizontal locomotion in mice. “Ambulations”
were recorded when a mouse interrupted an infrared beam adjacent to a
previously-interrupted beam in either the x- or y- plane of the chamber (above;
right). Repeated disruptions of the same beam were not counted.

Effects of VK4-40 alone

Morphine dose-response

Ambulations

We previously examined the effects of the selective D3R antagonist PG01037
(133-fold selectivity for D3R vs. D2R) using drug-induced hyperactivity as a
behavioral proxy for DA release within the nucleus accumbens. Interestingly,
we found that PG01037 enhances cocaine-induced hyperlocomotion while it
attenuates morphine-induced hyperlocomotion in mice. The potentiation of
psychostimulant effects could confound the potential use of D3R antagonists
for the treatment of OUD, since many opioid users co-abuse stimulants such
as cocaine. However, recent studies with more selective D3R antagonists
found that they do not enhance certain effects of cocaine while still reducing
opioid effects. It is currently unknown what impact these highly-selective D3R
antagonists will have on cocaine-induced hyperactivity and/or dopamine
neurotransmission.

VK4-40 selectively attenuates morphine-induced hyperlocomotion

Ambulations

In light of the increasing rates of opioid abuse in the US, the search for viable
medications to treat opioid abuse disorder (OUD) has become ever more
urgent. Opioids exert their abuse-related effects in part by indirectly increasing
dopamine (DA) neurotransmission in the mesolimbic system, a dopaminergic
projection arising in the ventral tegmental area and terminating in the nucleus
accumbens. The DA D3 receptor (D3R), which belongs to the D2 family of
dopamine receptors (D2, D3 , D4 receptor subtypes), is highly expressed in
these brain regions and has shown strong potential as a pharmacotherapeutic
target for the treatment of OUD. More specifically, D3R antagonists have been
shown by us and others to attenuate the abuse-related behavioral effects of
opioids without producing adverse side effects associated with nonselective
D2-like receptor antagonists.
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Figure 4. Time course effects of morphine-induced locomotion following pretreatment with VK4-40. Vehicle, 3, 10, or 20 mg/kg of
VK4-40 was administered 30 min before (A) 5.6 mg/kg morphine, or (B) 18 mg/kg morphine. Each data point represents mean ±SEM
total ambulations recorded in 5-min bins.
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